A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

A Phase 1 study testing LY3549492 in people with Type 2 Diabetes, run by Eli Lilly and Company at 3 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks. Read more about this study

Who is it for?: Ages 18 to 65 years
Conditions the study is for: Type 2 Diabetes
What is being tested?: LY3549492
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 36 participants
Where: 3 sitesChina
Study dates: 25 Jul 2025to 27 Jan 2026
Phase: Phase 1
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Are native Chinese
Have type 2 diabetes for at least 6 months
Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months
Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10%
Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2
Have had a stable body weight for the 3 months prior to screening
Women must not be of childbearing potential

Who cannot join

Have type 1 diabetes or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization
Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness
Have a clinically significant gastric emptying abnormality
Have or have a history of pancreatitis
Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease
Have a personal or family history of multiple endocrine neoplasia syndrome type 2 or medullary thyroid carcinoma

Show all 10Show fewer

Have an uncontrolled endocrine abnormality
Have an abnormal blood pressure or pulse rate
Have a 12-lead electrocardiogram (ECG) abnormality
Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data

Trial locations and contacts

3 sites in 1 country.

China3 sites

Peking University People's Hospital
Beijing, 100033
West China Hospital of Sichuan University
Chengdu, 610041
Peking University First Hospital
Dongcheng District, 100009

Other trials in China

About this study

Official title: A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.

Conditions: Type 2 Diabetes
Being tested: LY3549492, Placebo
Medical subject headings: Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

LY3549492Drug
Administered orally
PlaceboDrug
Administered orally

Study groups in NCT07073170
Study group	Role	What they receive
LY3549492 Dose 1	Experimental	Participants will receive LY3549492 orally Receives: Drug: LY3549492
LY3549492 Dose 2	Experimental	Participants will receive LY3549492 orally Receives: Drug: LY3549492
LY3549492 Dose 3	Experimental	Participants will receive LY3549492 orally Receives: Drug: LY3549492
Placebo	Placebo comparator	Participants will receive Placebo orally Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Measured: Baseline through Week 14

Secondary outcomes (2)

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3549492
Measured: Predose through Week 13
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3549492
Measured: Predose through Week 13

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

25 Jul 202527 Jan 2026

First posted18 Jul 2025
Study start25 Jul 2025
Primary completion27 Jan 2026
Study completion27 Jan 2026

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 36 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07073170
Sponsor's protocol ID: 27335
Other IDs: J3H-GH-GZNH
Status last verified: Mar 2026
First submitted: 10 Jul 2025
Last updated: 3 Mar 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

All Type 2 Diabetes trials

Study at a glance

From the registry record, last updated by the sponsor on 3 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
ClinicalTrials.gov ID: NCT07073170
Acronym / sponsor ID: 27335
Conditions: Type 2 Diabetes
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 36 participants (actual)
Lead sponsor: Eli Lilly and CompanyIndustry (pharma, biotech, devices)
Study start: 25 Jul 2025 (actual)
Primary completion: 27 Jan 2026 (actual)
Study completion: 27 Jan 2026 (actual)
First posted: 18 Jul 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.

Study design

Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 4

Arm	Type	Receives
LY3549492 Dose 1	Experimental	Drug: LY3549492Participants will receive LY3549492 orally
LY3549492 Dose 2	Experimental	Drug: LY3549492Participants will receive LY3549492 orally
LY3549492 Dose 3	Experimental	Drug: LY3549492Participants will receive LY3549492 orally
Placebo	Placebo comparator	Drug: PlaceboParticipants will receive Placebo orally

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

Are native Chinese
Have type 2 diabetes for at least 6 months
Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months
Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10%
Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2

Key exclusion criteria (10 listed)

Have type 1 diabetes or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization
Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness
Have a clinically significant gastric emptying abnormality
Have or have a history of pancreatitis
Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
LY3549492Administered orally	Drug	LY3549492 Dose 1, LY3549492 Dose 2, LY3549492 Dose 3
PlaceboAdministered orally	Drug	Placebo

Primary outcome

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through Week 14
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

2 secondary outcomes

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3549492
Time frame: Predose through Week 13
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3549492
Time frame: Predose through Week 13

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2026.
Individual participant dataSharing planned: No

Related trials for Type 2 Diabetes

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director

Eli Lilly and Company

3 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing LY3549492 in people with Type 2 Diabetes, run by Eli Lilly and Company at 3 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration (time frame: Baseline through Week 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07073170.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026; AzTrials last refreshed its copy on 7 Nov 2026.